在患有晚期细胞癌的患者中,现实世界的治疗模式和临床结果
Elizabeth Esterberg1, Shrividya Iyer2, Saurabh P Nagar1
1RTI Health Solutions, Research Triangle Park, NC.
Clinical genitourinary cancer
|November 1, 2023
概括
免疫疗法 (IO) 组合,特别是IO + 氨酸激酶抑制剂 (TKI),在晚期细胞癌 (aRCC) 中显著改善无进展生存率 (PFS) 和到达下一次治疗的时间 (TTNT). 这些发现突显了组合疗法的有效性,而不是TKI单一疗法.
科学领域:
- 在瘤学瘤学.
- 医学科学 医学科学 医学科学
- 临床研究 临床研究
背景情况:
- 晚期细胞癌 (aRCC) 是一个重大的临床挑战,近30%的病例在转移阶段被诊断出来.
- 虽然免疫疗法 (IO) 已经改变了患者的护理,但关于其在aRCC中的有效性的现实数据有限.
研究的目的:
- 评估高级细胞癌 (aRCC) 患者的现实治疗结果.
- 为了比较不同一线治疗策略的疗效,包括氨酸激酶抑制剂 (TKI) 单疗法和各种免疫疗法 (IO) 组合.
主要方法:
- 从2018年1月至2020年12月期间治疗的498名aRCC患者的人口和临床数据的回顾性分析.
- 卡普兰-梅尔法用于估计总生存期 (OS) 和无进展生存期 (PFS).
- 多变量考克斯回归评估了治疗影响,控制IMDC风险,组织学和患者特征.
主要成果:
- 与TKI单独治疗相比,免疫疗法 (IO) 组合,特别是IO + TKI,显示PFS (HR:0.50) 和时间到下一次治疗 (TTNT) (HR:0.54) 显著更长 (HR:0.54).
- 与双IO治疗相比,IO + TKI组合显示了改善PFS和降低进展风险 (HR:0.52).
- 在IO组合和TKI单疗之间没有观察到统计学上显著的OS差异 (HR:0.66).
结论:
- 与TKI单一治疗相比,一线IO+TKI组合疗法在晚期细胞癌中提供更高的无进展生存率和时间到下一次治疗.
- 组合免疫疗法策略,特别是IO + TKI,代表了在现实环境中管理晚期细胞癌的有效方法.
相关概念视频
01:21Cancer Survival Analysis
357
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
357
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
01:28Chronic Kidney Disease III: Interprofessional Care
13
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
13
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:16Kidney Transplant III: Nursing Management
22
Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
22